DC-CIK联合化疗治疗中晚期食管鳞癌的临床疗效评价  

Evaluation on clinical efficacy of DC-CIK combined with hemotherapy in treating moderate and advanced esophageal carcinoma

作　　者：赵媛[1] 宁实 杨光[1] 张曙光[1] 

机构地区：[1]中国医科大学附属第一医院胸外科,沈阳110001 [2]武警辽宁省总队第二支队,沈阳110034

出　　处：《检验医学与临床》2015年第19期2823-2826,共4页Laboratory Medicine and Clinic

基　　金：国家自然科学青年科学基金资助项目(81201890);辽宁省自然科学基金资助项目(2013021002)

摘　　要：目的研究树突状细胞(DC)-细胞因子诱导的杀伤细胞(CIK)联合多西紫杉醇+顺铂化疗(DC方案)治疗中晚期食管鳞癌患者的临床疗效。方法选取100例中晚期食管鳞癌患者,将其随机分为治疗组与对照组,每组50例。两组患者均给予DC化疗,治疗组在化疗的基础上给予DC-CIK免疫细胞治疗,观察两组治疗后的近期疗效、不良反应与治疗前后外周血清肿瘤标志物的浓度及免疫功能。结果治疗后治疗组近期及远期临床疗效均优于对照组(P<0.05);治疗后两组外周血清角蛋白片段(cyfra211)、鳞状细胞癌相关抗原(SCC)、癌胚抗原(CEA)、糖类抗原(CA125)较治疗前有所降低(P<0.05)。治疗组外周血清CD3、CD8、CD56/CD3、CD16/CD3、IgG、IgM、IgA较治疗前有所升高(P<0.05),CD4/CD8较治疗前降低(P<0.05)、CD4较治疗前无明显改变(P>0.05)。对照组外周血清CD3、CD8、CD4、CD4/CD8、CD56/CD3、CD16/CD3较治疗前无明显改变(P>0.05),对照组IgG、IgM、IgA较治疗前降低(P<0.05)。治疗后治疗组外周血清cyfra211、SCC、CEA、CA125浓度均低于对照组(P<0.05)。治疗后治疗组外周血清CD3、CD8、CD56/CD3、CD16/CD3、IgG、IgM、IgA明显高于对照组(P<0.05),CD4/CD8明显低于对照组(P<0.05),CD4较对照组差异无统计学意义(P>0.05)。治疗组治疗中出现发热、寒战;两组患者治疗后均出现不同程度消化道反应、骨髓抑制,且治疗组发生率低于对照组(P<0.05)。结论 DC-CIK联合化疗能提高中晚期食管鳞癌的临床疗效且不良反应较小。Objective To investigate the clinical efficacy of dentritic cells cytokines induced killer cell （DC‐CIK） combined with the chemotherapy of cisplatin plus docetaxel（DC regimen） in treating moderate and advanced e‐sophageal squamous carcinoma .Methods 100 patients with moderate and advanced esophageal squamous carcinoma were randomly divided into the treatment group and the control group ,50 cases in each group .The two groups were treated with the DC regimen .On the basis of chemotherapy ,the treatment group was given the DC‐CIK immune cell therapy .The short‐term effect after treatment ,adverse reactions ,peripheral serum concentrations of tumor markers before and after treatment and immune function were observed in the two groups .Results The short‐term and long‐term clinical efficacies after treatment in the treatment group were significantly better than those in the control group （P〈 0 .05） ;the peripheral serum cyfra211 ,SCC ,CEA and CA125 levels after treatment in the two groups were de‐creased compared with before treatment （ P 〈 0 .05） ;after treatment ,the peripheral serum CD3 ,CD8 ,CD56/CD3 , CD16/CD3 ,IgG ,IgM and IgA in the treatment group were increased compared with before treatment （P 〈 0 .05） , while CD4/CD8 was decreased compared with that before treatment（P〈 0 .05） ,CD4 had no significant change com‐pared with before treatment（P〉 0 .05） .The peripheral serum CD3 ,CD8 ,CD4 ,CD4/CD8 ,CD56/CD3 and CD16/CD3 after treatment had no obvious changes compared with before treatment（P〉 0 .05） ,while the IgG ,IgM and IgA lev‐els after treatment were decreased compared with before treatment（P〈 0 .05） .The peripheral serum cyfra211 ,SCC , CEA and CA125 concentrations after treatment were lower than those in the control group（P〈 0 .05） ;peripheral ser‐um CD3 ,CD8 ,CD56/CD3 ,CD16/CD3 ,IgG ,IgM and IgA levels after treatment in the treatment group were signifi‐cantly higher those in the control group（P〈 0 .05） ,while CD4/CD8 was s

关 键 词：中晚期食管鳞癌 DC-CIK 临床疗效 肿瘤标记物 免疫功能 

分 类 号：R735.105[医药卫生—肿瘤]